Rokote Laboratories
Helsinki
About Rokote Laboratories
Rokote Laboratories develops COVID-19 vaccine. In their vaccine, the cells of the nasopharynx are designed to create the SARS-CoV-2 virus's spike protein, which triggers an immune response. The second-generation coronavirus vaccine FINCoVac 2.1, which aims to offer strong protection against the coronavirus's quickly evolving variants, is the current focus of product development at Rokote Laboratories. To establish the use of novel vaccine technology in Finland is the aim of the company's development work.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $10.6M
- Funding stage: Seed
- Last round: Debt Financing (Jul 2021)
- Website: rokote.com
Industries & Categories
Chemical, Health Care, Pharmaceutical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/rokote-laboratories-90056 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.